PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. [PDF]
, 2017 BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity.
Casas, Juan P +5 more
core +2 more sources
Advanced Science, EarlyView.Radiation induces polyploid giant cancer cells (PGCCs) that regenerate tumors through virus‐like budding. This process depends on a SNCG–FLOT2–CHMP4B signaling axis functioning in lipid raft microdomains. Disrupting these domains using statins or anti‐PCSK9 antibodies blocks PGCC budding, suppresses tumor repopulation, and enhances radiotherapy ...
Zheng Deng +20 more
wiley +1 more source
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Frontiers in Cardiovascular Medicine, 2021 The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits observed in patients that have followed PCSK9-targeted therapies.
Aureli Luquero +5 more
doaj +1 more source
Therapeutic Gene Editing in Dyslipidemias
Reviews in Cardiovascular MedicineDyslipidemia, characterized by abnormal lipid levels in the blood, significantly escalates the risk of atherosclerotic cardiovascular disease and requires effective treatment strategies.
Seyed Saeed Tamehri Zadeh +1 more
doaj +1 more source
PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
Mediators of Inflammation, 2020 Epicardial adipose tissue (EAT) has the unique property to release mediators that nourish the heart in healthy conditions, an effect that becomes detrimental when volume expands and proinflammatory cytokines start to be produced.
Elena Dozio +7 more
doaj +1 more source
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. [PDF]
PLoS ONE, 2016 PCSK9 is a secreted ligand and negative post-translational regulator of low-density lipoprotein receptor (LDLR) in hepatocytes. Gain-of-function (GOF) or loss-of-function (LOF) mutations in PCSK9 are directly correlated with high or low plasma LDL ...
Steve Poirier +4 more
doaj +1 more source
Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
Metabolites, 2022 In adults, elevated levels of circulating Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) have been associated with increased Low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and worse cardiovascular outcomes.
Yara Azar +11 more
doaj +1 more source
FoxO3 transcription factor and Sirt6 deacetylase regulate LDL-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression [PDF]
, 2013 Elevated LDL-cholesterol is a risk factor for the development of cardiovascular disease. Thus, proper control of LDL-cholesterol homeostasis is critical for organismal health.
Deng, Chu-Xia +4 more
core +1 more source
Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞
Journal of Lipid Research, 2008 Mutations within proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with dominant forms of familial hypercholesterolemia. PCSK9 binds the LDL receptor (LDLR), and addition of PCSK9 to cells promotes degradation of LDLR.
Shilpa Pandit +10 more
doaj +1 more source
Childhood Obesity and Familial Hypercholesterolemia: Genetic Diseases that Contribute to Cardiovascular Disease [PDF]
, 2014 Childhood obesity occurs as the result of an imbalance between caloric intake and energy expenditure. Genetic risk factors for obesity have become an area of research due to its permanency.
Caudle, Alyssa
core +1 more source